Alnylam Pharmaceuticals Inc SEC Filings

Tanguler Tolga reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 5,959 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 31,769 shares.

Fitzgerald Kevin Joseph reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 8,000 shares at a weighted average price of $321.24 per share. Following the reported transactions, holdings were 21,264 shares.

Poulton Jeffrey V. reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 59,802 shares.

An insider of ALNY has filed a notice to sell 2,041 common shares through UBS Financial Services on or about February 17, 2026 on Nasdaq, with an indicated aggregate market value of $677,531.58. The filing shows these shares were acquired on February 12, 2026 via a PSU (performance stock unit) transaction with the issuer.

The insider previously sold 12,128 common shares on November 17, 2025 for $5,483,998.14 and 2,290 common shares on January 13, 2026 for $848,062.57. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.

Alnylam Pharmaceuticals outlines its RNAi-focused business and long-term "Alnylam 2030" goals in its annual report, targeting at least 25% compound annual total revenue growth and ~30% non-GAAP operating margin by 2030. The company now has six marketed RNAi-based medicines and more than 20 clinical programs, including several in late-stage development across rare diseases, cardiometabolic conditions, and CNS disorders.

To support growth, Alnylam issued $661.3 million of 0.00% Convertible Senior Notes due 2028 and used cash to repurchase about $672.2 million principal of its 1.00% Convertible Senior Notes due 2027 for roughly $1.16 billion. It also established a secured $500 million revolving credit facility, which was undrawn at year-end aside from $17.5 million in letters of credit. Multiple collaborations with Roche, Regeneron, Sanofi, Novartis, Vir and others are intended to expand its pipeline and global reach.

Alnylam Pharmaceuticals reported a strong turnaround for 2025, driven by rapid growth in its RNAi medicines. Total revenues reached $3.71 billion, up 65% from 2024, while net product revenues rose 81% to $2.99 billion, led by AMVUTTRA for ATTR amyloidosis and steady growth in GIVLAARI and OXLUMO.

The company moved from a GAAP net loss of $278.2 million in 2024 to GAAP net income of $313.7 million in 2025; non-GAAP net income was $683.6 million. Fourth-quarter 2025 revenues were $1.10 billion, up 85% year over year, with total net product revenues more than doubling.

Management introduced its "Alnylam 2030" strategy, highlighting durable TTR leadership and long-term innovation, and issued 2026 guidance calling for $4.9–$5.3 billion in net product revenues and $400–$500 million in collaboration and royalty revenue. Cash, cash equivalents and marketable securities were $2.91 billion at year-end, supporting continued pipeline and manufacturing investments.

Alnylam Pharmaceuticals executive Pushkal Garg, EVP Chief R&D, reported equity award vesting and related tax sales. On January 11, 2026, he received 3,800 shares of common stock upon vesting of 40% of a performance-based stock unit granted on March 1, 2024. The award vested after Alnylam publicly reported $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, multiple small blocks of common stock were automatically sold by the company on his behalf to cover minimum statutory tax withholding obligations tied to this award. Following these transactions, Garg directly held 22,511 common shares, plus 431 shares held indirectly by a managed account and 250 shares held in a trust where his spouse is co‑trustee; he disclaims beneficial ownership of the trust shares.

Alnylam Pharmaceuticals Chief Executive Officer and director Yvonne Greenstreet reported equity awards and related share sales. On January 11, 2026, she acquired 19,003 shares of common stock at $0.0 upon vesting of 40% of a performance-based stock unit granted on March 1, 2024, after the company publicly reported $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, the company automatically sold multiple small blocks of Alnylam common stock on her behalf, coded as "S" transactions, pursuant to a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding. These sales occurred at weighted average prices ranging from about $353.53 to $377.82 per share. After the reported transactions, she beneficially owned 78,411 shares directly and 407 shares indirectly through a managed account.

Alnylam Pharmaceuticals executive Jeffrey V. Poulton, EVP and Chief Financial Officer, reported equity award vesting and related share sales. On January 11, 2026, he received 6,193 shares of common stock at $0.0 upon vesting of 40% of a performance-based stock unit granted on March 1, 2024, after the company reported $2.5 billion in annual net product revenue under GAAP. On January 12, 2026, the company automatically sold multiple small blocks of Poulton’s shares, coded as sales, under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding, at weighted average prices described in ranges from $353.53 to $374.89. Following these transactions, Poulton directly held 57,465 Alnylam shares and indirectly held 57 shares through a managed account, and the footnotes note additional shares acquired via the issuer’s 401(k) matching contribution program.